StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Madrigal Pharmaceuticals's EV/EBITDA was 2.0× on Feb 28, 2011.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2011Feb 28, 20112.0×+0.4
2010Dec 31, 20101.5×–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?